By Fineline Cube China-based biotech ImmVira has successfully secured its Series C+ financing, entering into agreements with a first batch of investors, including China Merchants China Direct Investments Ltd, Wuzhong Biomedical Industry Development Fund, and Qiandao Fund. The proceeds will be used to advance clinical studies of three product pipelines in the US and China, either as monotherapies or in combination with other drugs. Additionally, the funding will support an Investigational New Drug (IND) filing for oncolytic virus and exosome products, as well as the development and validation of new drugs based on the OvPENS platform.
Progress Since Series C Financing
Since completing its Series C financing round, ImmVira has achieved several milestones:
- The intratumoral injection program MVR-T3011 IT has demonstrated efficacy-related immune signals for head and neck cancer, sarcoma, and other indications in Phase II clinical trials in China and the US.
- MVR-T3011 IV (intravenous injection) has shown good safety results in Phase I clinical studies in both countries and has verified its clinical biological activity.
- The MVR-C5252 (brain tumor) program has been approved for clinical trials in the US and has received orphan drug designation (ODD).
- The MVR-T7 series (CAR-T/ADC/BiTE combined pipeline) is being prepared for an IND filing as a combination therapy.
- The company has officially launched the non-viral vector, namely, the targeted exocrine new drug pipeline, with the first three product designs completed. The production process exploration and IND filing for these products will be promoted going forward.
Partnerships and Collaborations
ImmVira has established strategic partnerships to further its clinical development efforts. The company is collaborating with Swiss major Roche on a clinical study of MVR-T3011 IT combined with Roche’s MEK inhibitor, Cobimetinib, in the US. Additionally, ImmVira has partnered with compatriot firm China Resources Bio to bolster the clinical development of MVR-C5252, a potential first-in-class glioma oncolytic virus product, in Greater China.-Fineline Info & Tech